financetom
Business
financetom
/
Business
/
Minda Corp aims to outgrow industry growth by 2x and expects margins at 11-12%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Minda Corp aims to outgrow industry growth by 2x and expects margins at 11-12%
Dec 19, 2022 6:31 AM

Share Market Live

NSE

In this latest episode of 'Inside Out - On the Road', the focus is on individual stocks, with in-depth analysis, deep dive into financials, and the key risk and triggers as we advance.

Minda Corporation is the stock in focus. In 2022, the stock is up nearly 10 percent but from the highs seen in April 2022, it is down 25 percent, and in one year even after the correction, it’s up 43 percent.

Minda Corp has a presence in the global automotive industry and is a manufacturer of automotive components for original equipment manufacturers (OEMs).

The company caters to passenger vehicles, commercial vehicles, motorcycles and scooters, off-road vehicles, and tier-1 manufacturers in India with a presence in overseas markets as well. It also caters to aftermarket and electric vehicles.

Read Here: Uno Minda to enhance its EV offerings with German joint venture

In an interaction with CNBC-TV18, Aakash Minda, executive director at Minda Corporation said the company is looking to outgrow industry growth by 2X.

He said in the next midterm to the long-term, the company would like to grow sustainably to about 12 percent, sustain at 11 percent and then grow up to 12 percent and then grow higher.

The focus is on premiumisation, exports in the 4-wheeler space, and adding more products in the 4-wheeler space. The company is also in talks with some players for mergers and acquisitions.

In the 'Swotlight' segment, CNBC-TV18's Sonal Bhutra talks about Neuland Laboratories, the company which is primarily into manufacturing active pharmaceutical ingredients for global pharmaceutical companies.

The company also provides end-to-end solutions for the pharmaceutical industry for chemistry-related services from the synthesis of library compounds to the supply of new chemical entities and intermediates at various clinical phases up to the commercial scale.

The stock saw stellar returns from January 2020 to May 2021, almost 500 percent and from those levels, the stock has fallen close to 38 percent.

Watch the video for more.

First Published:Dec 19, 2022 3:31 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved